| Home | E-Submission | Sitemap | Contact Us |  
top_img
Cancer Research and Treatment > Accepted Articles
doi: https://doi.org/10.4143/crt.2018.421    [Accepted]
Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry
Jung Kwon Kim1, Sung Han Kim2, Mi Kyung Song3, Jungnam Joo3, Seong Il Seo4, Cheol Kwak5, Chang Wook Jeong5, Cheryn Song6, Eu Chang Hwang7, Ill Young Seo8, Hakmin Lee1, Sung-Hoo Hong9, Jae Young Park10, Jinsoo Chung2, Korean Renal Cell Carcinoma Study Group
1Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
2Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea
3Biometric Research Branch, Center for Prostate Cancer, National Cancer Center, Goyang, Korea
4Department of Urology, Sungkyunkwan University College of Medicine, Seoul, Korea
5Department of Urology, Seoul National University College of Medicine, Seoul, Korea
6Department of Urology, University of Ulsan College of Medicine, Seoul, Korea
7Department of Urology, Medical School, Chonnam National University, Hwasun, Korea
8Department of Urology, Wonkwang University School of Medicine and Hospital, Iksan, Korea
9Department of Urology, Seoul St. Mary's Hospital, The Catholic University, Seoul, Korea
10Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea
Correspondence  Jinsoo Chung ,Tel: 82-31-920-1505, Fax: 82-31-920-2474 , Email: cjs5225@ncc.re.kr
Received: July 26, 2018;  Accepted: September 5, 2018.  Published online: September 7, 2018.
ABSTRACT
Purpose
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma. Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein.
Materials and Methods
From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS).
Results
The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: The median first-line PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p = 0.0014); 14, 7, and 2 months (p=0.0002); and 41, 21, and 8 months (p<0.0001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.0047); 10, 7, and 3 months (p=0.0023); and 50, 21, and 8 months (p<0.0001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS.
Conclusion
The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.
Key words: Non-clear cell, Metastatic renal cell carcinoma, Prognosis, Criteria, validation, Korean
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
  E-Mail
Share:      
METRICS
0
Crossref
0
Scopus
204
View
47
Download
Related article
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community